[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100330402":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":75,"collaborators":26,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":89,"minAge":90,"maxAge":26,"enrollmentInfo":91,"targetDuration":26,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"University of Aarhus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment arm","ACTIVE_COMPARATOR","5 mg of folic acid (1 tablet) per day for 12 weeks.",[13],"Drug: Folic Acid",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo arm","PLACEBO_COMPARATOR","PLACEBO (1 tablet) per day for 12 weeks.",[19],"Drug: Placebo Oral Tablet",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Folic Acid","5 mg pr day for 12 weeks",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo Oral Tablet","1 placebo pill pr day for 12 weeks",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Niels Fristrup, MD PhD","CONTACT","004520914161","niels.fristrup@rm.dk",[38,58],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Aarhus University Hospital, Department of oncology","RECRUITING","Aarhus","Central Region of Denmark","8000","Denmark","DK",{"type":47,"coordinates":48},"Point",[49,50],10.21076,56.15674,{"lat":50,"lon":49},[53,54],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"name":55,"role":34,"phone":56,"phoneExt":26,"email":57},"Anne Helland, Project nurse","004591167228","anheol@auh.rm.dk",{"facility":59,"status":40,"city":60,"state":26,"zip":61,"country":44,"countryCode":45,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Department of Oncology, Herlev Hospital","Herlev","2730",{"type":47,"coordinates":63},[64,65],12.43998,55.72366,{"lat":65,"lon":64},[68,72],{"name":69,"role":34,"phone":70,"phoneExt":26,"email":71},"Jesper Palshof, MD, PhD","+45 38683868","Jesper.Andreas.Palshof@regionh.dk",{"name":73,"role":74,"phone":26,"phoneExt":26,"email":26},"Anne Kirstine Moeller, MD PhD","SUB_INVESTIGATOR",{"type":76,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":79,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Niels Fristrup","Principal Investigator","Aarhus University Hospital","100330402","phase-2-folic-acid-supplement-versus-placebo-for-treating-mucositis-adverse-events-in-metastatic-renal-cell-carcinoma-patients-receiving-targeted-therapy-100330402",false,"NCT03581773","Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy","FASTERCC: Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy. A Randomized, Double-blind Trial From the Danish Renal Cancer Group (DARENCA Study-4)","DARENCA4","Target population: Patients with inoperable, locally advanced, or metastatic renal cell carcinoma.\n\nInclusion Criteria:\n\n1. Patients displaying CTCAE ≥2 mucositis during TKI, mTOR inhibitor or immunotherapy treatment.\n2. Signed written informed consent obtained prior to any study specific procedures.\n3. Patient must be willing and able to comply with the protocol.\n4. Age ≥ 18.\n5. Biopsy proven locally advanced or metastatic renal cell carcinoma.\n6. Females with a negative serum pregnancy test unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.\n7. Fertile women of childbearing potential (\\\u003C2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilization).\n8. Karnofsky Performance status ≥ 60%.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to folic acid.\n2. Use of prednisolone more than 10 mg daily.",true,"ALL","18 Years",{"count":92,"type":93},100,"ESTIMATED","INTERVENTIONAL",[96],"PHASE2","FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy. A randomized, double-blind trial from the Danish renal cancer group (DARENCA study-4)",[99,100],"Mucositis","Stomatitis","2026-04-28",{"date":103,"type":104},"2026-05-04","ACTUAL",{"date":106,"type":104},"2017-12-20",{"date":108,"type":93},"2029-09-01",{"name":77,"class":6},2]